Posters

Defining the Genotype-CRIM Status Relationship in a Large Cohort of 215 Patients with Infantile-onset Pompe Disease

Defining the Genotype-CRIM Status Relationship in a Lar...

20

Growth Outcomes and Safety of Navepegritide in Children with Achondroplasia: Results of the ApproaCH Trial Open Label Extension

Growth Outcomes and Safety of Navepegritide in Children...

16

Mitochondrial Function in Fibroblasts from a Patient with Congenital NAD Deficiency due to Biallelic NADSYN1 Variants

Mitochondrial Function in Fibroblasts from a Patient wi...

13

PROTEIN TARGETS OF CO2-DEPENDENT LYSINE CARBOXYLATION IN THE MOUSE BRAIN

PROTEIN TARGETS OF CO2-DEPENDENT LYSINE CARBOXYLATION I...

72

EVIDENCES OF INTERLEUKIN 20 RECEPTOR A BLOCKADE BY RITONAVIRIN TRIPLE NEGATIVE BREAST CANCER CELLS

EVIDENCES OF INTERLEUKIN 20 RECEPTOR A BLOCKADE BY RITO...

80

REDOX PROTEOMICS REVEALS A RECIPROCAL REDOX-METABOLIC COUPLING THAT REGULATES CIRCADIAN CLOCK

REDOX PROTEOMICS REVEALS A RECIPROCAL REDOX-METABOLIC C...

656

COPPER-DRIVEN REDOX MODULATION AMPLIFIES THYMOQUINONE- MEDIATED DNA DAMAGE, APOPTOSIS SIGNALING, AND TUMOR SUPPRESSION IN COLORECTALCANCER

COPPER-DRIVEN REDOX MODULATION AMPLIFIES THYMOQUINONE- ...

281

PROTECTIVE EFFECT OF ENHANCED MITOCHONDRIAL TURNOVER BY POTENT SMALL MOLECULE INHIBITOR OF USP14

PROTECTIVE EFFECT OF ENHANCED MITOCHONDRIAL TURNOVER BY...

3140

FINDING TROUBLE IN PAIRS: A SYNTHETIC GENETIC INTERACTION FRAMEWORK IN CHLAMYDOMONAS REINHARDTII

FINDING TROUBLE IN PAIRS: A SYNTHETIC GENETIC INTERACTI...

227

NUCLEOCYTOPLASMIC TRANSPORT INHIBITION AS A POTENTIAL THERAPEUTIC TARGET IN ENDOMETRIAL CANCER

NUCLEOCYTOPLASMIC TRANSPORT INHIBITION AS A POTENTIAL T...

61

DYSREGULATED AKT–FOXO3A AXIS IMPAIRS REDOX RESILIENCE IN RTT SYNDROME

DYSREGULATED AKT–FOXO3A AXIS IMPAIRS REDOX RESILIENCE I...

3135

Oxidative Signaling in Plants

Oxidative Signaling in Plants

126

ATAF1 IS A NOVEL SUBSTRATE OF SnRK2 KINASES

ATAF1 IS A NOVEL SUBSTRATE OF SnRK2 KINASES

157

DEVELOPMENTAL THERAPEUTICS—MOLECULARLY TARGETED AGENTS AND TUMOR BIOLOGY

DEVELOPMENTAL THERAPEUTICS—MOLECULARLY TARGETED AGENTS ...

159928

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrad...

DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

1988

Pilot study on outcome and antitumor efficacy of an autologous cancer cell vacci...

GASTROINTESTINAL CANCER—COLORECTAL AND ANAL

GASTROINTESTINAL CANCER—COLORECTAL AND ANAL

1639

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8...